Abstract
Usually, it takes quite some time until new insights from basic or clinical research are ultimately transferred into clinical routine. On the other hand, there are still many hurdles to directly provide and use routine data in the context of basic and clinical research. Specifically, no coherent software solution is available that allows a convenient and immediate bidirectional transfer of data between concrete treatment contexts and research settings.
Here, we present a generic framework that integrates health data (e.g., clinical, molecular) and computational analytics (e.g., model predictions, statistical evaluations, visualizations) into a clinical software solution which simultaneously supports both patient-specific healthcare decisions and research efforts, while also adhering to the requirements for data protection and data quality. Specifically, we emerge from a recently established generic data management concept, for which we designed and implemented a web-based software framework that integrates data analysis, visualization as well as computer simulation and model prediction with audit trail functionality and a regulation-compliant pseudonymization service. Within the front-end application, we established two tailored views: a clinical (i.e., treatment context) perspective focusing on patient-specific data visualization, analysis and outcome prediction, and a research perspective focusing on the exploration of aggregated, but pseudonymized data.
We illustrate the application of our generic framework by two use-cases from the field of haematology/oncology. Our implementation demonstrates the feasibility of an integrated generation and backward propagation of data analysis results and model predictions at an individual patient level into clinical decision-making processes.
Author summary Patient-oriented research is based on comprehensive, quality-assured medical data that is visualized and analysed to gain knowledge. Based hereon, computer models can be developed, which e.g., calculate risk scores or predict treatment success. Such approaches can be used for risk staging or for selecting the optimal therapy for a specific patient. In recent years, a lot of efforts have been made to develop generic concepts for data processing and for providing the data in the research context. What has been missing so far is a suitable software infrastructure to facilitate the direct backward propagation of scientific results into everyday clinical practice to support the treating clinicians in their decision-making processes. To close this gap, we designed a generic software framework into which, in principle, any computational model or algorithm can be integrated. For demonstration purposes, we developed a web application that integrates two mathematical models from the field of haematology, specifically relating to chronic myeloid leukaemia (CML). Both models calculate the leukaemia recurrence probability of a specific patient, after the intended stopping of the applied therapy. The particular prediction is based on patient-specific molecular diagnostic data and can be used for personalized treatment adaptation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the German Federal Ministry of Education and Research (https://www.bmbf.de/en) in the framework of the ERA-Net ERACoSysMed JTC-2 project “prediCt” (Grant number 031L0136A) to IR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Not applicable. Although the shown clinical data is structurally identical to data from clinical trials, we linked different sets of clinical data to artificially created personal data. The created set of artificial patient data are used to illustrate the framework functionality only.
